Haier Biomedical Showcases Automated Biostorage at ISPE Singapore
Analysis based on 7 articles · First reported Jul 20, 2026 · Last updated Sep 01, 2026
The showcase reinforces Haier Biomedical's positioning in the growing automated biostorage and pharmaceutical infrastructure market, potentially supporting its revenue growth trajectory. Positive financial metrics reported at the event may boost investor sentiment for the company's stock.
Haier Biomedical (SHA: 688139) showcased a portfolio of automated and digital solutions at the International Society for Pharmaceutical Engineering Singapore Conference & Exhibition 2026, held August 20-21 at Suntec Singapore. The company debuted its automated -80°C storage solution internationally and featured its pilot freeze dryer, highlighting its expansion from low-temperature storage into integrated biopharmaceutical infrastructure. The company also presented its Smart RFID ULT Storage Solution, which connects physical samples with digital records to improve traceability and workflow efficiency. Haier Biomedical reported strong first-half 2026 results: pharmaceutical customer revenue grew 23% year-over-year, laboratory solutions revenue grew 19%, and AI-related businesses accounted for 18% of revenue, up 3 percentage points from 2025. The event underscores the company's strategic shift toward multi-product portfolios, scenario-specific solutions, and ongoing services for pharmaceutical R&D, production, and quality control.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard